• 1
    DiMagno EP, Reber HA, Tempero MA. Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117: 146384.
  • 2
    Jemal A, Murray T, Samuels A. Cancer statistics 2003. CA Cancer J Clin 2003; 53: 526.
  • 3
    Pleskow DK, Berher HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19–9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 7049.
  • 4
    Goggins M, Canto M, Hruban RH. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74: 2438.
  • 5
    Wright GL, Cazares LH, Leung SM et al. ProteinChip surface enhanced laser desorption/ionization mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999; 2: 26476.
  • 6
    Conrads TP, Fusaro VA, Ross S et al. High-resolution serum proteome features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 16378.
  • 7
    Coombes KR, Fritsche HA, Clarke C et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49: 161523.
  • 8
    Qu Y, Adam BL, Thornquist M. Data reduction using a discrete wavelet transformation in discriminant analysis of very high dimensinality data. Biometrics 2003; 59: 14351.
  • 9
    Orvisky E, Drake SK, Martin BM et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006; 6: 2895902.
  • 10
    Yasui Y, Pepe M, Thompson ML et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003; 4: 44963.
  • 11
    Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21: 116477.
  • 12
    Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006; 27: 2519.
  • 13
    Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 5727.
  • 14
    Kozak KR, Amneus MW, Pusey SM et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 123438.
  • 15
    Petricoin EF, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 15768.
  • 16
    Bañez LL, Prasanna P, Sun L et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003; 170: 4426.
  • 17
    Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 360914.
  • 18
    Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296304.
  • 19
    Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003; 3: 23106.
  • 20
    Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158: 1491502.
  • 21
    Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62: 186875.
  • 22
    Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 8608.
  • 23
    Yu Y, Chen S, Wang LS et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68: 7986.
  • 24
    Brand R, Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis 1998; 16: 24252.
  • 25
    Brugge WR, Lewandrowski K, Lee-Lewandrowski E et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 13306.
  • 26
    Song MH, Lee SK, Kim MH et al. EUS in the evaluation of pancreatic cystic lesions. Gastrointest Endosc 2003; 57: 8916.
  • 27
    Sedlack R, Affi A, Vazquez-Sequeiros E, Norton ID, Clain JE, Wiersema MJ. Utility of EUS in the evaluation of cystic pancreatic lesions. Gastrointest Endosc 2002; 56: 5437.
  • 28
    Le Borgne J, De Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multi-institutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999; 230: 15261.
  • 29
    Johnson CD, Stephens DH, Charboneau JW, Carpenter HA, Welch TJ. Cystic pancreatic tumors: CT and sonographic assessment. AJR Am J Roentgenol 1988; 151: 11338.
  • 30
    Ahmad NA, Kochman ML, Lewis JD, Ginsberg GG. Can EUS alone differentiate between malignant and benign cystic lesions of the pancreas? Am J Gastroenterol 2001; 96: 3295300.
  • 31
    PelaezLuna M, Chari ST. Cyst fluid analysis to diagnose pancreatic cystic lesions an as yet unfulfilled promise. Gastroenterology 2006; 130: 10079, discussion 1009.
  • 32
    Abbruzzese J. Molecular diagnosis of pancreatic and biliary cancer: ready for broad implementation? Cancer J 2000; 6: 2824.
  • 33
    Barkin JS, Goldstein JA. Diagnostic and therapeutic approach to pancreatic cancer. Biomed Pharmacother 2000; 54: 4009.
  • 34
    Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S. Protein analysis on a proteomic scale. Nature 2003; 422: 20815.
  • 35
    Poon TC, Yip TT, Chan AT et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49: 75260.
  • 36
    Rai AJ, Zhang Z, Rosenweig J et al. Proteomic approaches to tumor marker discovery: identification of biomarkers for ovarian cancer. Arch Pathol Lab Med 2002; 126: 151826.
  • 37
    Khalid A, Finkelstein S, McGrath K. Molecular diagnosis of solid and cystic lesions of the pancreas. Clin Lab Med 2005; 25: 10116.
  • 38
    Howng SL, Hsu HC, Cheng TS et al. A novel ninein-interaction protein CGI-99, blocks ninein phosphorylation by GSK3beta and is highly expressed in brain tumors. FEBS Lett 2004; 566: 1628.
  • 39
    Cui YZ, Wu JW, Zong MJ et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer 2009; 124: 161421.